Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Underlines Disapproval Of Drug-Supplement Combos In Letter To P&G

This article was originally published in The Tan Sheet

Executive Summary

FDA notes once again that combination OTC drug and dietary supplement products are unapproved new drugs with a warning letter sent Oct. 29 to Procter & Gamble about Vicks DayQuil Plus Vitamin C and VicksNyQuil Plus Vitamin C

You may also be interested in...



OTC Firms Should Improve Monograph Compliance, Registration – CDER

CDER recommends the OTC industry ensure product innovations comply with monographs or have FDA approval prior to marketing. Umbrella-branding and facility registration rank high for the drug center in 2013.

OTC Firms Should Improve Monograph Compliance, Registration – CDER

CDER recommends the OTC industry ensure product innovations comply with monographs or have FDA approval prior to marketing. Umbrella-branding and facility registration rank high for the drug center in 2013.

FDA Warns Matrixx On Combination Supplement/Drug Products

Matrixx Initiatives’ troubled history with FDA continues with a warning two of its products are unapproved new drugs because they combine supplements with OTC drugs.

Related Content

Topics

UsernamePublicRestriction

Register

PS103477

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel